Latest Financial Losses News

OFX Group is investigating unauthorised access to data involving some clients and people who have interacted with the company. The fintech says there is currently no evidence that client accounts, funds or services were affected, but the scope of the incident remains unclear.

DigiCo Infrastructure REIT is using US asset sales to lower leverage and concentrate capital on its Australian data centre pipeline, led by the fully funded 88MW SYD1 project. The strategy comes alongside a $100.8 million statutory loss, higher distributions and FY27 guidance for 15.0 cents per security.

Solstice Minerals has emerged from FY2026 with a larger exploration story, a A$45.3 million liquidity base and drilling that extends Nanadie beyond its existing resource footprint. The company remains loss-making and pre-production, leaving future value tied to resource growth and exploration execution.

Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.

Kyron Capital Group (ASX: KYN) reported a $51.9 million net loss for FY26, completing a $125 million recapitalisation to stabilise its balance sheet and reduce gearing. The Group's assets under management shrank to $1.8 billion following strategic divestments and mandate exits.

Fiducian Group posted solid underlying earnings growth in FY2026, boosted by a 7% rise in funds under management, advice and administration, while absorbing a one-off $7.95 million ASIC penalty that halved statutory profits.

Macarthur Minerals narrowed its loss to $1.82 million for FY26, bolstered by a major new investor and joint venture at its Lake Giles iron ore project in Western Australia.

Chorus has reported a rise in its fibre regulated asset base to NZD 6 billion for 2025, alongside a significant NZD 101 million under-earn on its maximum allowable revenue, resulting in a NZD 76.3 million wash-up balance to be carried into the next regulatory period.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

Synlait Milk Limited has reported a significant half-year loss driven by manufacturing setbacks and market pressures, alongside a strategic recovery roadmap focused on asset sales and operational overhaul.

Frontier Digital Ventures reported an 18% decline in statutory revenue to A$54.8 million for 2025, while operating EBITDA surged 205% to A$9.1 million, despite a net loss of A$18 million impacted by a significant goodwill impairment and a fraud incident in Colombia.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.